Allergan Unlimited Company, formerly Allergan Limited, is an Ireland-based pharmaceutical company. The Company is focused on developing, manufacturing and commercializing branded pharmaceutical, device, biologic, surgical and regenerative medicine products for patients around the world. The Company's products primarily focus on four key therapeutic areas, including medical aesthetics, eye care, central nervous system and gastroenterology.

Employees

Sector

Pharmaceuticals

More about the company

Delayed NYSE			5-day change	1st Jan Change
- ^USD	-.--%		+1.73%	+0.97%

09-17	Allergan Aesthetics Presents New Clinical Data Evaluating Skin Quality Improvements in Individuals Taking Medical Weight Loss Medications	CI
09-15	Allergan Aesthetics Introduces the FACTS Principles for Exosome-Based Skincare Technologies	CI

Market Cap	63.66B 56.88B 53.07B 48.2B 90.78B 6,158B 91.46B 638B 249B 3,132B 239B 234B 10,068B	P/E 2018	-8.76x	P/E 2019	-11.9x
Enterprise Value	80.96B 72.34B 67.49B 61.3B 115B 7,832B 116B 811B 317B 3,983B 304B 297B 12,805B	EV / Sales 2018	4.24x	EV / Sales 2019	4.98x
Free-Float	99.9%	Yield 2018	2.15%	Yield 2019	1.55%

09-17	Allergan Aesthetics Presents New Clinical Data Evaluating Skin Quality Improvements in Individuals Taking Medical Weight Loss Medications	CI
09-15	Allergan Aesthetics Introduces the FACTS Principles for Exosome-Based Skincare Technologies	CI
09-01	Allergan Aesthetics Launches Skinmedica Barrier Calming Cream and Ha5 Hydra Collagen Facial Mist	CI
04-07	Allergan Aesthetics Opens New Ami Training Center in Austin	CI
03-31	Allergan Aesthetics Announces Fourth Annual CoolMonth With Deals On CoolSculpting	CI
03-30	Allergan Aesthetics Presents Findings on Safety and Efficacy of Repeat Trenibote Treatments and Data on Medical Weight Loss Aesthetics Patient Behaviors At the 2026 American Academy of Dermatology Meeting	CI
03-19	Allergan Aesthetics Reveals Evolution in Approach to Modern Aesthetic Treatments with Comprehensive Global Survey and New Educational Solutions	CI
03-04	Allergan Aesthetics Shares Medical Weight Loss Data and the Changing Profile of Patients	CI
11-12	Allergan Aesthetics Unveils New Data at 2025 American Society for Dermatologic Surgery Annual Meeting Showcasing Transformative Innovation and Portfolio Excellence	CI
25/09/25	AllAllergan Aesthetics to Showcase Multimodal Treatment Approach and Continued Commitment to Skin Quality At AMWC Dubai	CI
19/08/25	Allergan Aesthetics Unveils Its Newest Hydration Hero	CI
30/06/25	U.S. Food and Drug Administration Accepts for Review Allergan Aesthetics Premarket Approval Application for Skinvive by Juvederm for the Improvement of Neck Appearance	CI
12/02/25	Allergan Aesthetics to Launch Three New Training Centers in the U.S. Expanding Access to High Quality Aesthetics Training	CI

01/04/24	Court Dismisses Class Action Against Biopharmaceutical Company For Failing To Disclose Progress Of Competitor; Second Circuit Affirms Dismissal Of Putative Class Action Against Allergan; Eleventh Circuit Affirms That "Toxic" Lender Qualified As A "Dealer" Under The Exchange Act Due To High-Volume Trading; Delaware Court Of Chancery Invalidates Governance Rights In Stockholder Agreement	AQ
20/04/22	Allergan, an AbbVie Company, to Present New Data from its Eye Care Portfolio at the 2022 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting	AQ
06/04/22	Allergan, an AbbVie Company, Announces Positive Topline Phase 3 Results Evaluating Investigational Twice-Daily Administration of VUITY 1.25% in Adults with Age-Related Blurry Near Vision	AQ
22/03/22	AbbVie and Allergan Aesthetics to Present New Research Across Dermatology Portfolio at 2022 AAD Annual Meeting	AQ
10/12/21	Allergan - VUITY 1.25%, the First and Only FDA-Approved Eye Drop to Treat Age-Related Blurry near Vision, is Now Available	AQ

Allergan plc Stock

Stocks

AGN

IE00BY9D5467

Pharmaceuticals

Valuation: Allergan plc

Latest news: Allergan plc

Press Releases: Allergan plc

News in other languages: Allergan plc

Managers and Directors: Allergan plc

Latest insider transactions

Other Pharmaceuticals

Financials

Company Profile

20/04/21	Planète Bourse : La revue de presse du mardi 20 avril 2021
07/05/20	EN DIRECT DES MARCHES : Air France KLM, ArcelorMittal, Legrand, Natixis, Peugeot, Eurofins, Zalando, Facebook...
07/05/20	La Chine repart, mais Washington veille
06/05/20	EN DIRECT DES MARCHES : Danone, Sanofi, Crédit Agricole, Arkema, Neoen, Eurofins, BMW, Novo Nordisk...
06/05/20	Trump franchit le Rubicon

Manager	Title	Age	Since
Alex Thurman DFI	Director of Finance/CFO	56	01/12/2016
Robert Michael PSD	President	55	08/05/2020

Director	Title	Age	Since
Robert Michael BRD	Director/Board Member	55	08/05/2020
Scott Reents BRD	Director/Board Member	-	08/05/2020
Ryan Quigley BRD	Director/Board Member	-	08/05/2020

Date	Insider	Type	Main position	Quantity	% Market Cap.
08/05/20	James D'Arecca	Issuer sale	Controller/Auditor	19,495	0.0059%
08/05/20	Adriane Brown	Issuer sale	Director	2,916	0.0009%
08/05/20	Matthew Walsh	Issuer sale	Chief Financial Officer	67,678	0.0206%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ALLERGAN PLC	-.--%	+1.73%	-	-	63.66B
ELI LILLY AND COMPANY	+2.70%	+2.73%	+40.91%	+110.31%	1,060B
JOHNSON & JOHNSON	+1.44%	-2.38%	+36.83%	+63.95%	623B
ABBVIE INC.	+1.75%	+3.73%	+16.55%	+83.05%	480B
MERCK & CO., INC.	+0.60%	-1.73%	+62.98%	+37.46%	352B
ROCHE HOLDING AG	-1.25%	+1.52%	+21.63%	+41.24%	345B
NOVARTIS AG	-0.77%	+0.75%	+11.68%	+34.96%	274B
ASTRAZENECA PLC	-0.69%	-1.45%	-5.31%	+11.48%	249B
AMGEN INC.	+2.60%	-2.00%	+39.77%	+54.44%	223B
GILEAD SCIENCES, INC.	+1.82%	-1.48%	+25.75%	+96.48%	182B
Average	+0.33%	-0.26%	+27.87%	+59.26%	385.17B
Weighted average by Cap.	+0.04%	+0.07%	+31.50%	+70.26%

	2018	2019
Net sales	15.79B 14.11B 13.16B 11.95B 22.51B 1,527B 22.68B 158B 61.79B 777B 59.27B 57.99B 2,497B	16.09B 14.38B 13.41B 12.18B 22.94B 1,556B 23.11B 161B 62.97B 792B 60.4B 59.09B 2,545B
Net income	-5.1B -4.55B -4.25B -3.86B -7.27B -493B -7.32B -51.05B -19.95B -251B -19.13B -18.72B -806B	-5.27B -4.71B -4.39B -3.99B -7.52B -510B -7.57B -52.8B -20.63B -259B -19.79B -19.36B -834B
Net Debt	21.89B 19.56B 18.25B 16.57B 31.22B 2,118B 31.45B 219B 85.67B 1,077B 82.18B 80.4B 3,462B	17.3B 15.46B 14.43B 13.1B 24.68B 1,674B 24.86B 173B 67.72B 851B 64.96B 63.56B 2,737B